Which statement best describes an appropriate approach to assessing menopause-related symptoms and hormone therapy eligibility?

• A. Assess vasomotor symptoms
• B. Discuss nonhormonal options only
• C. Assess vasomotor symptoms, sleep, mood, and urogenital atrophy; review risk factors; discuss nonhormonal options; if HT is considered, evaluate contraindications and tailor regimen
• D. Refer to gynecologic oncology

Answer: (C)

A comprehensive, individualized assessment of menopause symptoms and hormone therapy eligibility involves evaluating a range of symptom domains, not just vasomotor symptoms, and weighing risk factors before deciding on treatment. Start by identifying the full burden of the menopause experience: vasomotor symptoms, sleep disruption, mood changes, and urogenital atrophy (vaginal dryness and dyspareunia) because these areas often impact quality of life and daily functioning. At the same time, review relevant risk factors and contraindications for hormone therapy, such as personal or family history of estrogen-sensitive cancers, thromboembolic disease, active liver disease, or other conditions that would make estrogen use unsafe. This risk review guides safe, personalized decision-making.

Discuss nonhormonal options as part of the conversation, recognizing they may be appropriate for some patients or temporarily used while others are explored. If hormone therapy is considered, tailor the regimen to the individual: choose the appropriate route and formulation, determine the correct dose, and set a realistic duration with plans for re-evaluation. This approach ensures symptom relief is balanced with safety, rather than addressing symptoms in isolation.

Referencing a gynecologic oncology specialist is not typically necessary for standard menopausal symptom management and hormone therapy candidacy, which is why the broader, patient-centered assessment is preferred.